doi: 10.3389/fphar.2014.00026 Effects of IKur blocker MK-0448 on human right atrial action potentials from patients in sinus rhythm and in permanent atrial fibrillatio
The interest in class III drugs has increased over the last decades as being potent antiarrhythmic a...
In the wake of demographic change in Western countries atrial fibrillation has reached an epidemiolo...
Rationale: Understanding atrial fibrillation (AF) requires integrated understanding of ionic current...
Selective blockers of the Kv1.5 channel have been developed for the treatment of atrial fibrillation...
BackgroundSelective inhibitors of Kv1.5 channels are being developed for the treatment of atrial fib...
BACKGROUND: -We evaluated the viability of I(Kur) as a target for maintenance of sinus rhythm in pat...
The human electrophysiological and pharmacological properties of XEN-D0101 were evaluated to assess ...
Current pharmacological therapy against atrial fibrillation (AF), the most common cardiac arrhythmia...
Purpose: To assess the efficacy of the I-kr-blocker almokalant attempting to convert chronic atrial ...
Inhibition of the atrial ultra-rapid delayed rectifier potassium current (IKur) represents a promisi...
Abstract: There is a clear unmet medical need for new phar-macologic therapies for the treatment of ...
Atrial fibrillation (AF) is the most common tachyarrhythmia in the adult population and is a major c...
Chronic β-adrenoceptor antagonist (β-blocker) treatment in patients is associated with a potentially...
The voltage-gated potassium channel, Kv1.5, which underlies the ultrarapid delayed rectifier current...
AIMS: We aimed at examining the acetylcholine-dependent inward-rectifier current (IKAch) as a target...
The interest in class III drugs has increased over the last decades as being potent antiarrhythmic a...
In the wake of demographic change in Western countries atrial fibrillation has reached an epidemiolo...
Rationale: Understanding atrial fibrillation (AF) requires integrated understanding of ionic current...
Selective blockers of the Kv1.5 channel have been developed for the treatment of atrial fibrillation...
BackgroundSelective inhibitors of Kv1.5 channels are being developed for the treatment of atrial fib...
BACKGROUND: -We evaluated the viability of I(Kur) as a target for maintenance of sinus rhythm in pat...
The human electrophysiological and pharmacological properties of XEN-D0101 were evaluated to assess ...
Current pharmacological therapy against atrial fibrillation (AF), the most common cardiac arrhythmia...
Purpose: To assess the efficacy of the I-kr-blocker almokalant attempting to convert chronic atrial ...
Inhibition of the atrial ultra-rapid delayed rectifier potassium current (IKur) represents a promisi...
Abstract: There is a clear unmet medical need for new phar-macologic therapies for the treatment of ...
Atrial fibrillation (AF) is the most common tachyarrhythmia in the adult population and is a major c...
Chronic β-adrenoceptor antagonist (β-blocker) treatment in patients is associated with a potentially...
The voltage-gated potassium channel, Kv1.5, which underlies the ultrarapid delayed rectifier current...
AIMS: We aimed at examining the acetylcholine-dependent inward-rectifier current (IKAch) as a target...
The interest in class III drugs has increased over the last decades as being potent antiarrhythmic a...
In the wake of demographic change in Western countries atrial fibrillation has reached an epidemiolo...
Rationale: Understanding atrial fibrillation (AF) requires integrated understanding of ionic current...
DOI
Add to ORKG